Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.17469 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- System level network data and models attack cancer drug resistance Márk Kerestély Dávid Keresztes Levente Szarka Borbála M. Kovács Klára Schulc Dániel V. Veres Peter Csermely British Journal of Pharmacology Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small‐scale interactomes and signalling network models of drug resistance guide directed drug development. Recently, proteome‐wide human interactome and signalling network data have become available, which have been extended by drug–target interactions, drug resistance‐inducing mutations, as well as by several cancer and drug resistance‐related multi‐omics datasets. System level signalling network models have become available examining therapy resistance, performing in silico clinical trials, and conducting large, in silico drug combination screens. Drug resistance network data and models have become interoperable and reliable. These advances paved the road for building proteome‐wide drug resistance models. LINKED ARTICLES This article is part of a themed issue Network Medicine and Systems Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.8/issuetoc 10.1111/bph.17469 http://creativecommons.org/licenses/by/4.0/